Allergies is an indication for drug development with over 200 pipeline drugs currently active. According to GlobalData, preregistered drugs for Allergies have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Allergies compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Allergies overview
Allergies result from an immune system reaction to substances that typically don’t affect others. Common triggers include pollen, dust mites, mold spores, pet dander, foods, insect stings, and medications. While the immune system’s usual role is to fight infections, allergies involve an exaggerated response to harmless elements, influenced by both genetics and the environment. Symptoms vary from runny nose and sneezing to severe outcomes like anaphylaxis. Diagnosis relies on skin and blood tests, and treatments encompass medications, allergy shots, and avoidance of triggering substances. Allergies can range from minor nuisances to potentially life-threatening conditions, necessitating proper management.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Allergies, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
